UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 367

Sortiert nach

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

JNCI : Journal of the National Cancer Institute, 2012-01, Vol.104 (2), p.125-132

2012

Volltextzugriff (PDF)

NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence

Oncogene, 2016-06, Vol.35 (25), p.3282-3292

2016

Volltextzugriff (PDF)

Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia

BMC urology, 2021-03, Vol.21 (1), p.47-47, Article 47

2021

Volltextzugriff (PDF)

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies

Urology (Ridgewood, N.J.), 2019-07, Vol.129, p.160-164

2019

Volltextzugriff (PDF)

Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study

British journal of cancer, 2012-06, Vol.107 (1), p.207-214

2012

Volltextzugriff (PDF)

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial

JNCI : Journal of the National Cancer Institute, 2005-03, Vol.97 (6), p.433-438

2005

Volltextzugriff (PDF)

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

Cancer, 2000-06, Vol.88 (S12), p.2989-2994

2000

Volltextzugriff (PDF)

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

Urology (Ridgewood, N.J.), 2004-09, Vol.64 (3), p.537-541

2004

Volltextzugriff (PDF)

EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER

The Journal of urology, 2004-09, Vol.172 (3), p.915-919

2004

Volltextzugriff (PDF)

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study

Prostate cancer and prostatic diseases, 2013-09, Vol.16 (3), p.254-259

2013

Volltextzugriff (PDF)

Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study

Prostate cancer and prostatic diseases, 2016-06, Vol.19 (2), p.180-184

2016

Volltextzugriff (PDF)

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

Journal of internal medicine, 2012-07, Vol.272 (1), p.85-92

2012

Volltextzugriff (PDF)

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens

Prostate cancer and prostatic diseases, 2017-12, Vol.20 (4), p.413-417

2017

Volltextzugriff (PDF)

Diabetes and prostate cancer risk in the REDUCE trial

Prostate cancer and prostatic diseases, 2011-12, Vol.14 (4), p.326-331

2011

Volltextzugriff (PDF)

Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE

Prostate cancer and prostatic diseases, 2016-06, Vol.19 (2), p.202-208

2016

Volltextzugriff (PDF)

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens

Scandinavian journal of urology, 2018-11, Vol.52 (5-6), p.328-332

2018

Volltextzugriff (PDF)

Risk behaviours and benign prostatic hyperplasia

BJU international, 2004-06, Vol.93 (9), p.1241-1245

2004

Volltextzugriff (PDF)

Erythropoietin Therapy

The New England journal of medicine, 1997-03, Vol.336 (13), p.933-938

1997

Volltextzugriff (PDF)

Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial

Controlled clinical trials, 2000-12, Vol.21 (6), p.273S-309S

2000

Volltextzugriff (PDF)

The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

The New England journal of medicine, 1992-10, Vol.327 (17), p.1185-1191

1992

Volltextzugriff (PDF)

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

The New England journal of medicine, 1991-04, Vol.324 (17), p.1156-1161

1991

Volltextzugriff (PDF)

A prospective randomized comparison of three blood conservation strategies for radical prostatectomy

Anesthesiology (Philadelphia), 1999-07, Vol.91 (1), p.24-33

1999

Volltextzugriff (PDF)

Overdiagnosis of Prostate Cancer

Journal of the National Cancer Institute. Monographs, 2012-12, Vol.2012 (45), p.146-151

2012

Volltextzugriff (PDF)

T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer

The Journal of urology, 1993-09, Vol.150 (3), p.1018-1023

1993

Volltextzugriff (PDF)

1 – 25 von 367

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(333)
Mit Volltextzugriff
(231)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up

NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence

Body size throughout the life-course and incident benign prostatic hyperplasia-related outcomes and nocturia

Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies

Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO Study

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: Findings From the Initial Screening Round of a Randomized Trial

The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma

Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia

EFFECT OF THE DUAL 5α-REDUCTASE INHIBITOR DUTASTERIDE ON MARKERS OF TUMOR REGRESSION IN PROSTATE CANCER

Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study

Greater extent of prostate inflammation in negative biopsies is associated with lower risk of prostate cancer on repeat biopsy: results from the REDUCE study

Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study (R1)

The combination of histological prostate atrophy and inflammation is associated with lower risk of prostate cancer in biopsy specimens

Diabetes and prostate cancer risk in the REDUCE trial

Baseline subject characteristics predictive of compliance with study-mandated prostate biopsy in men at risk of prostate cancer: results from REDUCE

The association of atrophy in baseline prostate biopsy and lower prostate cancer grade in radical prostatectomy specimens

Risk behaviours and benign prostatic hyperplasia

Erythropoietin Therapy

Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial

The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer

A prospective randomized comparison of three blood conservation strategies for radical prostatectomy

Overdiagnosis of Prostate Cancer

Prevention and early detection of prostate cancer

T-Cell Subsets Required for Intravesical BCG Immunotherapy for Bladder Cancer

Suchergebnisse filtern